MedTrace Logo

Effect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure.

NCT07605260 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-22

No results posted yet for this study

Summary

Local data regarding the effectiveness and safety of mannitol has been scarce. Therefore, the current study was planned, aiming to compare the change in mean anterior chamber depth and intraocular pressure (IOP) and to determine the frequencies of perioperative complications during cataract surgery in groups receiving mannitol versus placebo.

Conditions

  • Cataract

Interventions

DRUG

Mannitol

After employing standard protocol for dilatation, intravenous mannitol at 1g/kg over a period of 30 minutes was administered to the patients.

DRUG

Placebo

After employing standard protocol for dilatation, patients were given a placebo.

Sponsors & Collaborators

  • Muhammad Aamir Latif

    lead OTHER

Principal Investigators

  • Muhammad Irtiza · Pakistan Air Force (PAF) Hospital Islamabad

  • Muhammad Azam, FCPS · Pakistan Air Force (PAF) Hospital Islamabad

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07605260 on ClinicalTrials.gov